To explore the relationship between LXN polymorphisms and the risk of oral mucositis in patients receiving chemoradiotherapy for nasopharyngeal carcinoma.
Genetic analysis of LXN polymorphisms in a cohort of patients
Assessment of oral mucositis occurrence during treatment
Comparison of genetic profiles with toxicities observed
Identified significant associations between specific LXN polymorphisms and increased risk of oral mucositis
Found that certain genetic variants may predispose individuals to higher treatment toxicity
Established a genetic basis for personalized treatment approaches in nasopharyngeal carcinoma
Abstract
This study is the first to establish a link between NPC chemoradiotherapy-induced oral mucositis risk and LXN polymorphisms in the Chinese Han population.